Cogar A A, Hartenberger C H, Ohls R K
Department of Pediatrics, University of New Mexico, Albuquerque, NM 87131-5311, USA.
Biol Neonate. 2000 Feb;77(2):105-8. doi: 10.1159/000014203.
Increased endothelin-1 (ET-1) production following recombinant erythropoietin (Epo) administration is a presumed etiology for the hypertension reported in some adults. It is unknown whether Epo has similar effects in preterm infants.
Serum ET-1 and Epo concentrations were measured prior to study, and following the second and third doses in 20 preterm infants receiving intravenous (IV) or subcutaneous (SC) Epo. Blood pressures were monitored prior to Epo administration and during the first, second, and third dose.
Infants (963 +/- 54 g birth weight, 27.4 +/- 0.6 weeks gestational age, 18 +/- 3 days of life; mean +/- SEM) had baseline Epo concentrations of 5.5 +/- 1.3 mU/ml and ET-1 concentrations below the lower limits of detection (<1 pg/ml). Epo concentrations were 1,848 +/- 274 and 1,672 +/- 295 mU/ml following the second and third IV dose, respectively, while Epo concentrations were 420 +/- 92 and 290 +/- 35 mU/ml after the second and third SC dose, respectively (p < 0.005, SC versus IV). ET-1 concentrations remained below the limits of detection in all but 6 infants, whose concentrations were <3.3 pg/ml. Blood pressures did not increase above baseline in either group during the study period.
Despite the wide range of Epo concentrations measured, no correlation was observed between Epo concentrations, ET-1 concentrations, and blood pressure during the 1-week study period. The long-term effects of Epo on ET-1 concentrations and blood pressure in preterm infants require further study.
重组促红细胞生成素（Epo）给药后内皮素-1（ET-1）生成增加被认为是一些成人高血压的病因。Epo在早产儿中是否有类似作用尚不清楚。
对20例接受静脉（IV）或皮下（SC）Epo治疗的早产儿，在研究前、第二次和第三次给药后测定血清ET-1和Epo浓度。在Epo给药前以及第一次、第二次和第三次给药期间监测血压。
婴儿（出生体重963±54g，胎龄27.4±0.6周，出生后18±3天；均值±标准误）的基线Epo浓度为5.5±1.3mU/ml，ET-1浓度低于检测下限（<1pg/ml）。第二次和第三次IV给药后Epo浓度分别为1848±274和1672±295mU/ml，而第二次和第三次SC给药后Epo浓度分别为420±92和290±35mU/ml（p<0.005，SC与IV相比）。除6例婴儿（其浓度<3.3pg/ml）外，所有婴儿的ET-1浓度均低于检测下限。在研究期间，两组的血压均未升高至基线以上。
尽管所测Epo浓度范围很广，但在为期1周的研究期间，未观察到Epo浓度、ET-1浓度和血压之间的相关性。Epo对早产儿ET-1浓度和血压的长期影响需要进一步研究。
